Metabolic safety of the etonogestrel contraceptive implant in healthy women over a 3-year period
| Autor: | Helena Malerba, Mila Pontremoli Salcedo, Mirela Foresti Jiménez, Luiz C. Vilodre, Jaqueline Villas-Boas, Patrícia El Beitune |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
medicine.medical_specialty Population Gastroenterology Body Mass Index Young Adult 03 medical and health sciences 0302 clinical medicine Insulin resistance Interquartile range Internal medicine Contraceptive Agents Female medicine Humans Insulin Prospective Studies 030212 general & internal medicine education Prospective cohort study Etonogestrel education.field_of_study Desogestrel 030219 obstetrics & reproductive medicine business.industry Body Weight Obstetrics and Gynecology medicine.disease Endocrinology Reproductive Medicine Women's Health Female Implant Insulin Resistance business Contraceptive implant Dyslipidemia medicine.drug |
| Zdroj: | European Journal of Obstetrics & Gynecology and Reproductive Biology. 202:51-54 |
| ISSN: | 0301-2115 |
| Popis: | To ascertain whether placement of the etonogestrel contraceptive implant induces significant changes in carbohydrate and lipid metabolism, as reflected by metabolic parameters, in healthy women.Prospective cohort study of 213 healthy patients who received etonogestrel implants. Weight, BMI, blood pressure and a comprehensive metabolic profile were assessed at baseline, 1, 2 and 3 years. In 21 of the 213 participants, AUC for glucose levels, fasting insulin levels at baseline and year 3 (immediately before implant removal), HOMA-IR score, and the QUICK index were assessed. Parameters were expressed as median and interquartile range. The Wilcoxon test and ANOVA were used for comparison of measurements after implant placement (significance level p0.05).Median age was 26 years (range, 22-31.5). Results showed a trend toward increase of the variables weight (63.3-66.1) and BMI (24.7-25.7) and a decrease in TC (172-161.5), TG (75-69.5), and LDL (100.5-98.5) (p0.05). Of the metabolic variables, FBG (85-88) and HDL (53-46) had significant differences (p0.002). In the subgroup of 21 patients, there were reductions in insulin levels (9.65 vs. 8.4mU/dL, p=0.03), HOMA scores (2.06 vs. 1.75, p=0.02), QUICK index (0.34 vs. 0.35, p=0.03), TC (178 vs. 160mg/dL, p=0.001), HDL (51 vs. 46mg/dL, p=0.009), and LDL (110 vs. 100mg/dL, p=0.035).These results provide evidence of the metabolic safety of the ENG implant in healthy women over a 3-year period. Indeed, implant placement induces changes consistent with a lower risk of insulin resistance and dyslipidemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect